Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Orphacol ruling bolsters EU orphan exclusivity rules

This article was originally published in SRA

Executive Summary

Another European court ruling has confirmed the important role of the EU orphan drug regulation in encouraging companies to conduct R&D into medicines for rare diseases, and helped to clarify the rules regarding the orphan market exclusivity period.


Related Content

Changes To EU Orphan Similarity Concept Could Change Innovation Threshold For 10-Year Exclusivity